Welcome to the website of the
Hereditary TTP Registry
Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) or Upshaw-Schulman Syndrome (USS) is an ultra-rare and complex blood coagulation disease
read more about hereditary TTP
At present, the Hereditary TTP Registry has enrolled 231 participants from 18 different countries
click here to know which sites are involved
«The fact that the medical research of a son of the Mississippi Delta, born in Louise, MS in 1929, is being continued by a team of researchers all over the world, still excites me!»

Cristie Upshaw Travis
Daughter of Dr. Jefferson D. Upshaw
The Hereditary TTP Registry participated in the first-in-human study evaluating a recombinant human ADAMTS13 as therapeutic option in the treatment of congenital TTP
click here to read more about the study

Takeda: TAK-755 shows positive Phase 3 data in patients with cTTP

11 January 2023

Results are From First and Only Phase 3 Trial in cTTP, an Ultra-Rare Disease with Limited Treatment Options
cTTP is Caused by a Deficiency in ADAMTS13 Protease;¹ TAK-755 Is Designed to Replace Missing or Deficient ADAMTS13 Enzyme²
Takeda Plans to Seek Marketing Authorization for TAK-755 as the First ADAMTS13 Replacement Therapy for the Treatment of cTTP
to know more, click here